PPIDT00220
Drug Information
| Name | Reslizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06602 |
| Type | biotech |
| Indication | Indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intravenous |
10 MG/ML
|
| Injection, solution, concentrate | Intravenous |
10 mg/1mL
|
| Solution | Intravenous |
10 mg / mL
|